Login to Your Account

I.V. Vernakalant Still Under Review

Cardiome Generates Buzz with Phase II Data, Deal Speculation

By Jennifer Boggs

Tuesday, March 18, 2008
Shares of Cardiome Pharma Corp. got a nice boost Monday after the company reported promising interim results from a Phase IIb study showing that its arrhythmia drug oral vernakalant significantly increased the median time to relapse compared to placebo. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription